Compare · GRAL vs ILMN
GRAL vs ILMN
Side-by-side comparison of GRAIL Inc. (GRAL) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRAL and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $33.97B, about 9.2x GRAL ($3.69B).
- ILMN has been more active in the news (11 items in the past 4 weeks vs 7 for GRAL).
- ILMN has more recent analyst coverage (25 ratings vs 12 for GRAL).
- Company
- GRAIL Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $3.69B
- $33.97B
- 1M return
- -
- +18.79%
- 1Y return
- -
- +127.94%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 7
- 11
- Recent ratings
- 12
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest GRAL
- Amendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.
- GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
- SEC Form SCHEDULE 13G filed by GRAIL Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.
- SEC Form 10-Q filed by GRAIL Inc.
- GRAIL Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- GRAIL Reports Second Quarter 2026 Financial Results
- GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
- GRAIL to Announce Second Quarter 2026 Financial Results
- Director Chase William J was granted 276 shares, increasing direct ownership by 0.65% to 42,978 units (SEC Form 4)
Latest ILMN
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 8-K filed by Illumina Inc.
- SEC Form 3 filed by new insider Coletti Julie Ann
- SEC Form FWP filed by Illumina Inc.
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)